Literature DB >> 7943003

Emotional and neurocognitive deficits in fragile X.

W E Sobesky1, B F Pennington, D Porter, C E Hull, R J Hagerman.   

Abstract

We have studied the neurocognitive deficit in premutation and full mutation women as compared to control women and to explore the relationship between those deficits and the incidence of emotional problems. Four groups of women were examined: two fragile X (fra(X)) negative control groups, one of which grew up in fra(X) families and one not; and two DNA positive groups, one with a premutation (CGG repeats < 200) and one with an expanded mutation (CGG repeats > 200). All women were assessed using the MMPI-2, the SADS-L, and a battery of neuropsychological tests. Full mutation women had lower scores on composite measures of executive function and nonverbal function. There was no difference between the groups in terms of the lifetime incidence of depressive and anxiety disorders on the SADS-L. Full mutation women displayed Lie scales higher than the other groups on the MMPI-2. Neurocognitive measures were not related to SADS-L diagnoses but were related to the Lie scale on the MMPI-2. Finally, number of CGG repeats was related to the neuropsychological variables and the Lie scale.

Entities:  

Mesh:

Year:  1994        PMID: 7943003     DOI: 10.1002/ajmg.1320510416

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  16 in total

1.  Fragile-X: neuropsychological test performance, CGG triplet repeat lengths, and hippocampal volumes.

Authors:  P Jäkälä; T Hänninen; M Ryynänen; M Laakso; K Partanen; A Mannermaa; H Soininen
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

2.  Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors.

Authors:  Allyn McConkie-Rosell; Brenda Finucane; Amy Cronister; Liane Abrams; Robin L Bennett; Barbara J Pettersen
Journal:  J Genet Couns       Date:  2005-08       Impact factor: 2.537

3.  Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers.

Authors:  James A Bourgeois; Andreea L Seritan; E Melina Casillas; David Hessl; Andrea Schneider; Ying Yang; Inderjeet Kaur; Jennifer B Cogswell; Danh V Nguyen; Randi J Hagerman
Journal:  J Clin Psychiatry       Date:  2010-08-24       Impact factor: 4.384

Review 4.  Implications of the FMR1 Premutation for Children, Adolescents, Adults, and Their Families.

Authors:  Anne Wheeler; Melissa Raspa; Randi Hagerman; Marsha Mailick; Catharine Riley
Journal:  Pediatrics       Date:  2017-06       Impact factor: 7.124

5.  Behavioral assessment of social anxiety in females with Turner or fragile X syndrome.

Authors:  Katarzyna Lesniak-Karpiak; Michèle M M Mazzocco; Judith L Ross
Journal:  J Autism Dev Disord       Date:  2003-02

6.  Fronto-striatal dysfunction and potential compensatory mechanisms in male adolescents with fragile X syndrome.

Authors:  Fumiko Hoeft; Arvel Hernandez; Sudharshan Parthasarathy; Christa L Watson; Scott S Hall; Allan L Reiss
Journal:  Hum Brain Mapp       Date:  2007-06       Impact factor: 5.038

7.  Chronological age, but not FMRP levels, predicts neuropsychological performance in girls with fragile X syndrome.

Authors:  Amy A Lightbody; Scott S Hall; Allan L Reiss
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2006-07-05       Impact factor: 3.568

Review 8.  Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.

Authors:  John A Tsiouris; W Ted Brown
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

9.  Trajectory and Predictors of Depression and Anxiety Disorders in Mothers With the FMR1 Premutation.

Authors:  Jane E Roberts; Bridgette L Tonnsen; Lindsay M McCary; Amy L Ford; Robert N Golden; Donald B Bailey
Journal:  Biol Psychiatry       Date:  2015-07-31       Impact factor: 13.382

10.  Fragile X- associated Neuropsychiatric Disorders: A Case Report.

Authors:  Maria Melinda Tan; Jeanne Barbara Dy; Maria Jimena Salcedo-Arellano; Flora Tassone; Randi J Hagerman
Journal:  Future Neurol       Date:  2019-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.